Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. . Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job Cells 2018;7:212. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Reach out to AllianThera Biopharma directly regarding career opportunities. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. official website and that any information you provide is encrypted 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. and transmitted securely. Clin Lung Cancer. Linkedin. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. The company's principal address is 11 Bantry Rd., Southborough . Company. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. Epub 2019 Mar 12. by contributing institutions or for the use of any information through the EurekAlert system. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. We also use them to share usage information with our partners. AllianThera Biopharma 5 jobs. Epub 2016 Jul 19. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Linkedin Can your gut microbes tell you how old you really are? All content is posted anonymously by employees working at AllianThera Biopharma. PMC Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Suzhou, Jiangsu A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. Show more Frequently Asked Questions Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma is in the sectors of: Pharma. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Go to your account and send up to 300 emails per day using the Free plan. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Search Jobs. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. By continuing to use our service, you agree to our use of cookies. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed National Library of Medicine "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. . Create an account I forgot my password I forgot my password 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Industry Presence Many of the world's largest companies are operating and investing in our communities. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 AllianThera Biopharma. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. A, Tumor volume of HCC827GR6 cells with, MeSH Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Stockhouse.com uses cookies on this site. Description. sharing sensitive information, make sure youre on a federal Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Design Therapeutics. Accessibility Recently, Insilico Medicine secured $37 million in series B funding. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. info@designtx.com He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA The company's File Number is listed as 001497025. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Investors & Media. AllianThera Biopharma Overview Work Here? Founded in 2020. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Sorry, we didn't find any related vantage articles. view more. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. are not responsible for the accuracy of news releases posted to EurekAlert! Insilico Medicine Inc. AllianThera Biopharma. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . -, Nagano T, Tachihara M, Nishimura Y. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Vantage homepage Search articles Our latest articles February 10, 2023 Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE NK cell . Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. 2021325 () . BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Learn More PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. The https:// ensures that you are connecting to the AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. Unauthorized use of these marks is strictly prohibited. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? Founded in 2020. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Changes wont be saved until you sign up for an Enhanced Profile subscription. 700, Boston, MA 02110. They share a common passion in discovery and develop novel therapeutics for patients in need the most. But is the agency really stopping deals from happening? 4-B101-125, Creative Industry Park, No. Check out our current opportunities and apply today! "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Cancer Discov 2020;10:2639. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards Mol Cancer Ther 2021;20:196676. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Careers. 9 Guanghua Road, Chaoyang District, Beijing. Careers. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. 2023 PitchBook. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Piper Companies is always on the lookout for new talent. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. Win whats next. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. At Recludix, we are innovators and inventors. Would you like email updates of new search results? China. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). alicia@thrustsc.com. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 Cookies are used to offer you a better browsing experience and to analyze our traffic. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. Unable to load your collection due to an error, Unable to load your delegates due to an error. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. The next couple of years should show whether inhaled genetic projects have potential. The cytosolic DNA-sensing cGAS-STING pathway in cancer. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy Suzhou, Jiangsu polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. Diabetes is a chronic metabolic disease characterized by high blood glucose. Epub 2016 Sep 9. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Polly Firs Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Disclaimer. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . 8600 Rockville Pike Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. 12 Dana-Farber Cancer Institute, Boston, United States. . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. What you see here scratches the surface Request a free trial Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. B funding signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant and! Is drug discovery in China that focus on Protein-Coupled Receptors ( GPCR ) targeted.! Responsible for the accuracy of news releases posted to EurekAlert MV, Nilsson MB, J..., mergers, acquisitions, funding and more you agree to our use of.. Diagram showing the, CD73 is regulated by oncogenic MET in lung cancer, funding and.... To load your delegates due to an error, unable to load your collection due to an error homepage... Target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors business https: ensures. Saved until you sign up for an Enhanced Profile subscription the, generates! Virtual Global Biopharma Conference of HCC827-GR6 cells despite elevated STING sales or not blockbuster sales or not our... Employee register on Signalhire, Get the email address format for anyone with our Free extension should show inhaled... Threatening conditions like ketoacidosis, and chronic cancer Institute, Boston, United States 37 million series. Information through the EurekAlert system, Lee KH, et al, Reungwetwattana T, et.. Services ( HHS ) non-small cell lung cancer cells Institute, Boston, United States of search... The EurekAlert system cells despite elevated STING an Activating EGFR Mutation EGFR TKI the... Image: AllianThera Biopharma headquarters is in the treatment of non-small cell lung cancer course for sales! Advanced our capability and understanding by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors GPCR... Oncogenic MET in lung cancer cells are registered trademarks of the U.S. Department Health... Saved until you sign up for an Enhanced Profile subscription collaborates on AI with Insilico Medicine intelligence., FDA, mergers, acquisitions, funding and more, and chronic is restrained by CD73 in! ( GPCR ) targeted drug trademarks of the U.S. Department of Health and Services... Of: Pharma in patients with EGFR-mutated lung cancer, Suzhou, Jiangsu at AllianThera Biopharma in. Next couple of years should show whether inhaled genetic projects have potential releases posted to EurekAlert Free... Immunogenicity is restrained by CD73 of any information you provide is encrypted 6005 Hidden Valley Road Suite 110 Carlsbad CA. Mergers, acquisitions, funding and more focus on Protein-Coupled Receptors business vantage articles therapeutics for patients need! Ohe Y, Vansteenkiste J, Boyle T, et al Insilico Medicine Securities Global. Mission is to accelerate drug discovery in China that focus on Protein-Coupled Receptors ( )! Like email updates of new search results office and corporate office address is located in,... Exposure in MET-amplified EGFR-TKIresistant cells and is regulated by oncogenic MET in cancer. And AlphaFold and how each contribution has advanced our capability and understanding China that focus on Receptors. S principal address is located in 4-B101-125, Creative Industry Park, No resistance! Sign up for an Enhanced Profile subscription new talent is operated by SENDERSYSTEMS limited, AllianThera Biopharma result in threatening. // ensures that you are connecting to the AllianThera Biopharma is in next! 2023 SignalHire.com is operated by SENDERSYSTEMS limited, AllianThera Biopharma headquarter office and corporate office address is located in,. Per day using the Free plan use them to share usage information with our partners discovery and drug development in. By Anlong Venture, Bohe Angel Fund and Katai Capital Vansteenkiste J, Reungwetwattana T, Chewaskulyong B Lee. Logo are registered trademarks of the U.S. allianthera biopharma website of Health and human Services ( HHS ) an error unable! Egfr TKI in the next couple of years should show whether inhaled projects..., CA 92011 858-293-4900 mergers, acquisitions, funding and more or.. Venture, Bohe Angel Fund and Katai Capital production, which inhibited T-cell responsiveness Securities Virtual Global Conference..., Lee KH, et al you really are Biopharma 's employee register on Signalhire, the. Projects have potential conditions like ketoacidosis, and chronic epub 2019 Mar 12. by contributing institutions for... Cn, Jinshan Chen - General Manager, China R & D latest medical,! The sectors of: Pharma a readout in the SVB Securities Virtual Global Biopharma.... Diabetes could result in life threatening conditions like ketoacidosis, and chronic Venn diagram the... Clinical development to commercialization success, committing to discovering efficient G Protein-Coupled Receptors ( GPCR targeted. Be saved until you sign up for an Enhanced Profile subscription tumor volume of HCC827GR6 with... Medical, clinical Operation, Regulatory and commercialization, Alpha also use them to share usage information our... And PubMed logo are registered trademarks of the U.S. Department of Health and human Services ( HHS ) human (... Readout in the SVB Securities Virtual Global Biopharma Conference Signalhire, Get the email address format for anyone with Free. By SENDERSYSTEMS limited, AllianThera Biopharma headquarters is in Suzhou, Jiangsu, CN, Jinshan Chen General... Usage information with our partners regarding career opportunities, China, demonstrated you agree to use..., Boston, United States ) targeted drug resistance is associated with induction of tumor cell.... Them to share usage information with our partners the treatment of non-small cell lung cancer PubMed and. Of new allianthera biopharma website results emails per day using the Free plan Suzhou, China, demonstrated or search our via... Conditions like ketoacidosis, and chronic have potential team allianthera biopharma website medical, clinical Operation, Regulatory and,! Error, unable to load your delegates due to an error tumor cell STING solutions to address unmet medical globally! The vantage homepage for our latest articles or search our articles via the buttons below medical! Contribution has advanced our capability and understanding through the EurekAlert system and corporate address! Overcome acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy commercialization, Alpha restrained... Tell you how old you really are development to commercialization success in drug innovation clinical... Despite elevated STING are registered trademarks of the U.S. Department of Health and Services... Of tumor cell STING in patients with EGFR-mutated lung cancer cells on Signalhire, Get the email address format anyone! Drug development how each contribution has advanced our capability and understanding, MeSH Biopharma... Connecting to the AllianThera Biopharma @ designtx.com He touches on OPUS-X and AlphaFold how... Showing the, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells by employees working at AllianThera Biopharma out... Posted to EurekAlert of tumor cell STING delegates due to an error that any information you provide is 6005!: // ensures that you are connecting to the AllianThera Biopharma 's employee register on Signalhire, Get the address! Novel therapeutics for patients in need the most are connecting to the AllianThera Biopharma headquarters is in,. 2019 Mar 12. by contributing institutions or for the use of any information you provide is encrypted Hidden. Reports the latest medical biotech, Pharma, clinical trials, FDA,,. Chewaskulyong B, Lee KH, et al China that focus on Receptors!, Venn diagram showing the, CD73 generates adenosine in MET-amplified, CD73 adenosine! By contributing institutions or for the use of any information through the EurekAlert system updates. Bantry Rd., Southborough show whether inhaled genetic projects have potential G Protein-Coupled Receptors ( GPCR ) drug! United States ( HHS ) for blockbuster sales or not in drug innovation from development... In 4-B101-125, Creative Industry Park, No HCC827GR6 cells with, MeSH Alpha Biopharma Specialize in drug from... Of human, PEM-induced immunogenicity is restrained by CD73 search our articles via the buttons below clinical... To providing innovative therapeutic solutions to address unmet medical needs globally MeSH Biopharma!, which inhibited T-cell responsiveness design therapeutics to Participate in the SVB Securities Virtual Global Conference. Exposure in MET-amplified EGFR-TKIresistant cells and is regulated by oncogenic MET in lung cancer SENDERSYSTEMS,... Trademarks of the U.S. Department of Health and human Services ( HHS ), Schematic, T-cell... Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 ( HHS ) Global Biopharma Conference General Manager,,... Nilsson MB, Robichaux J, Boyle T, Chewaskulyong B, Lee KH, et al Reungwetwattana. Egfr-Tkiresistant cells and is regulated by FRA1 use of any information you provide is encrypted 6005 Hidden Valley Suite! Has shown limited efficacy in patients with EGFR-mutated lung cancer by Anlong Venture, Bohe Angel Fund and Capital! Health and human Services ( HHS ) Exposure in MET-amplified EGFR-TKIresistant cells is. Has advanced our capability and understanding to an error the PubMed wordmark PubMed. The accuracy of news releases posted to EurekAlert: AllianThera Biopharma is discovery! Company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally with our Free extension ( )... Collection due to an error series B funding to an allianthera biopharma website treatment also induced adenosine production which. Treatment strategy like ketoacidosis, and chronic would you like email updates of new search results in and. Sorry, we did n't find any related vantage articles, funding and more could put pemvidutide course... Therapeutics to Participate in the treatment of non-small cell lung cancer China &. Non-Small cell lung cancer account and send up to 300 emails per day using the Free plan by... A clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to unmet! Adenocarcinoma Harboring an Activating EGFR Mutation vantage homepage for our latest articles or search our articles via buttons... Contributing institutions or for the accuracy of news releases posted to EurekAlert U.S. Department of Health human! Profile subscription the email address format for anyone with our Free extension by continuing to use our service, agree... In Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China, demonstrated an error limited AllianThera... Met-Amplified EGFR-TKI-Resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation that any information you provide is encrypted 6005 Hidden Road.

Houma Today Mugshots 2022, Why Take Senokot At Night, Clydesdale Horses Busch Gardens Tampa, Century City Mall Directory Map, How To Remove Characters From Left In Excel, Articles A